Testing will be performed by Biocept in the US, and HarlePhil Ventures will sell, market, distribute, and collect reimbursements in the Philippines.
The firm's second quarter revenues grew more than seven times year over year based on a large increase in billable samples.
The firm's total revenues increased 47 percent to $221,369 for the quarter, mainly driven by continued expansion of commercial liquid biopsy test volumes.
The company said that it intends to use the proceeds of the stock and warrant offering for working capital, as well as general corporate purposes.
Biocept hopes data from the study will support the clinical utility of its liquid biopsy test to detect drug resistance mutations in NSCLC.
Quest Diagnostics will offer the Target Selector lung cancer mutation detection test in that country through a reference agreement with Biocept.
Progenetics will market and distribute Biocept's complete portfolio of Target Selector liquid biopsy assays in Israel. Other terms of the agreement were not disclosed.
The firm saw its Q4 revenues rise to $218,000 year over year, mainly due to expansion of its commercial liquid biopsy testing business.
Under the agreement, members of the health plan will have covered access to Biocept's growing menu of circulating tumor cell and circulating tumor DNA tests.
Upon entering the agreement, Aspire purchased $1 million in common stock, and may purchase up to $14 million more at Biocept's discretion.
Bioethicists disagree with a research team's decision to allow the return of risk results for adult-onset conditions from a newborn sequencing project, according to Reuters.
Alterations to particular gene may enable the Quechua of Peru to better tolerate high-altitude life, Ars Technica reports.
Nature News reports that additional South Korean researchers have included the names of children on scientific papers when they did not contribute to the work.
In PLOS this week: statistical approach to prioritize rare variant searches, gene expression alterations in chronic obstructive pulmonary disease, and more.